(NASDAQ: MOR) Morphosys Ag's forecast annual revenue growth rate of 28.17% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Morphosys Ag's revenue in 2024 is $258,998,166.On average, 3 Wall Street analysts forecast MOR's revenue for 2024 to be $9,422,068,380, with the lowest MOR revenue forecast at $6,842,314,944, and the highest MOR revenue forecast at $11,282,985,251. On average, 3 Wall Street analysts forecast MOR's revenue for 2025 to be $17,797,700,503, with the lowest MOR revenue forecast at $13,500,119,717, and the highest MOR revenue forecast at $25,829,917,777.
In 2026, MOR is forecast to generate $18,842,065,728 in revenue, with the lowest revenue forecast at $16,997,528,842 and the highest revenue forecast at $20,686,602,614.